PRLD
What one share of Prelude Therapeutics holds
Pharmaceutical Preparations
Prelude Therapeutics Incorporated ("Prelude" or the "Company") is a precision oncology company built on a foundation of drug discovery excellence to deliver novel precision cancer medicines to underserved patients.
Prelude Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.27 |
|---|---|
| Profit | −$0.72 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.39 |
| Cash and investments | $1.90 |
| Book value | $1.68 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$16.52 | $0.47 | −$15.85 | — | −$29.61 |
| 2020 | — | −$4.56 | $0.05 | −$3.75 | — | — |
| 2021 | — | −$2.43 | $0.05 | −$1.86 | — | $6.00 |
| 2022 | — | −$2.44 | $0.06 | −$1.83 | — | $4.08 |
| 2023 | — | −$2.02 | $0.06 | −$1.83 | — | $4.32 |
| 2024 | $0.09 | −$1.68 | $0.01 | −$1.37 | — | $2.38 |
| 2025 | $0.16 | −$1.29 | $0.00 | −$0.73 | — | $1.09 |